Alzheon, Inc. is an American clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, focused on developing novel therapeutics for Alzheimer's disease and other neurodegenerative disorders. The company was founded in 2013 and is led by industry veterans with extensive experience in CNS drug development[1].
| Attribute | Value |
|---|---|
| Founded | 2013 |
| Headquarters | Cambridge, Massachusetts, USA |
| CEO | Susan L. Solomon |
| Market Cap | ~$200M (private) |
| Employees | ~50 |
| Lead Program | ALZ-801 (valiltramiprosate) |
| Program | Target/Mechanism | Indication | Phase | Status |
|---|---|---|---|---|
| ALZ-801 (valiltramiprosate) | Amyloid oligomer inhibitor | Alzheimer's disease | Phase 3 | APOLLOE4 trial |
| ALZ-201 | Amyloid oligomer inhibitor | Alzheimer's disease | Preclinical | Research |
| ALZ-401 | Tau aggregation inhibitor | Alzheimer's disease | Preclinical | Research |
| ALZ-601 | Next-gen oligomer inhibitor | Alzheimer's disease | Discovery | Preclinical |
Alzheon's therapeutic approach is grounded in the amyloid oligomer hypothesis, which posits that soluble toxic oligomers—rather than insoluble plaques—are the primary drivers of synaptic dysfunction and cognitive decline in Alzheimer's disease.
The company's core platform focuses on:
ALZ-801 (valiltramiprosate) is a small molecule that:
ALZ-801 is an oral small molecule that represents a first-in-class approach to Alzheimer's disease by directly targeting toxic amyloid-beta oligomers.
Study Design:
Key Results:
Phase 2 Biomarker Data:
The Phase 3 APOLLOE4 trial is designed to confirm efficacy in the specific population of APOE4 homozygous patients with early AD[2].
Study Design:
Regulatory Status:
Timeline:
Preclinical program targeting amyloid oligomers with an optimized chemical scaffold. Designed for broader patient population beyond APOE4 carriers.
Discovery-stage program targeting tau protein aggregation. Complements the amyloid platform to address multiple pathological hallmarks of AD.
Alzheon maintains a focused pipeline with a clear priority:
The company has pursued strategic partnerships to advance development:
| Year | Funding | Source |
|---|---|---|
| 2013 | $10M | Series A |
| 2017 | $30M | Series B |
| 2020 | $50M | Series C |
| 2024 | $100M | Series D / Financing |
| Company | Drug | Mechanism | Stage |
|---|---|---|---|
| Biogen/Eisai | Leqembi | Antibody (plaques) | Approved |
| Eli Lilly | Donanemab | Antibody (plaques) | Approved |
| Roche | Gantenerumab | Antibody (plaques) | Phase 3 |
| Alzheon | ALZ-801 | Oligomer inhibitor | Phase 3 |
Alzheon's approach offers several potential advantages:
| Name | Role | Background |
|---|---|---|
| Susan L. Solomon | CEO and Co-Founder | Former Merck executive, 20+ years CNS |
| Dr. Martin T. Young | Chief Scientific Officer | Former Pfizer, neurodegeneration research |
| Dr. Michael J. Fox | Board Member | Michael J. Fox Foundation founder |
| **Dr. James A. R. | Chief Medical Officer | Former Eli Lilly, AD clinical development |
As a private company, detailed financials are limited:
Alzheimer's Disease Treatment
Amyloid Cascade Hypothesis
APOE4 and Risk](/genetics/apoe4-alzheimers-risk)
Amyloid-Beta Oligomers
Alzheimer's Disease Clinical Trials
Biomarkers in Alzheimer's